Open AccessA Lower Incidence of Cytomegalovirus Infection in De Novo Heart Transplant Recipients Randomized to Everolimus
Author(s) -
James A. Hill,
Manfred Hummel,
Randall C. Starling,
Jon A. Kobashigawa,
Sergio V. Perrone,
J.M. Arizón,
Svein Simonsen,
Kamal Abeywickrama,
Christoph Bara
Publication year - 2007
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/01.tp.0000290686.68910.bd
Subject(s) - everolimus , medicine , cytomegalovirus , gastroenterology , regimen , incidence (geometry) , heart transplantation , azathioprine , randomized controlled trial , transplantation , immunology , herpesviridae , virus , disease , viral disease , physics , optics
Cytomegalovirus (CMV) infection in recipients of cardiac transplants is associated with higher rates of morbidity. A recent phase III trial showed highly significantly (P<0.001) lower CMV rates with the proliferation signal inhibitor everolimus compared to azathioprine (AZA). To better define this association, data on CMV risk factors were collected retrospectively and analyzed.